Conditional survival after surgical resection of primary retroperitoneal tumors: a population-based study

Zhao, Shutao; Zhao, Yixuan; Liu, Shuang; Zhang, Chao; Wang, Xudong

doi:10.1186/s12935-021-01751-z

Cancer Cell International

Table 3 Three-year conditional survival rates of patients with primary retroperitoneal tumors after surgical resection in relation to prognostic factors

From: Conditional survival after surgical resection of primary retroperitoneal tumors: a population-based study

Variable	COS3, %						CCSS3, %
	Years since diagnosis						Years since diagnosis
	Basline	1y	2y	3y	4y	5y	Basline	1y	2y	3y	4y	5y
Overall	71.8	72.9	76.5	77.9	79.6	79.3	77.1	78.1	81.3	82.7	84.9	85.8
Age (year)
< 65	75.8	76.3	78.9	82.1	84.1	83.3	79.0	79.8	81.7	84.8	87.6	88.6
≥ 65	65.5	66.9	71.9	69.5	70.3	70.5	73.9	75.0	80.6	78.4	79.1	79.6
d (< 65 vs. ≥ 65)	0.23	0.21	0.17	0.31	0.35	0.31	0.12	0.12	0.03	0.16	0.24	0.26
Sex
Male	69.5	73.6	76.2	76.2	76.8	75.5	75.1	79.5	81.7	81.7	82.1	83.9
Female	73.8	72.3	76.7	79.3	81.9	82.3	78.7	76.9	85.0	83.4	87.2	87.3
d (male vs. female)	− 0.10	0.03	− 0.01	− 0.08	− 0.13	− 0.17	− 0.09	0.06	− 0.08	− 0.04	− 0.14	− 0.10
Marital status
Married	73.3	76.6	79.8	79.6	78.9	79.6
Unmarried	71.9	70.9	74.8	81.0	82.8	79.4
Unknown	67.8	64.1	68.6	70.7	79.8	78.0
d (married vs. unmarried)	0.03	0.13	0.12	− 0.03	− 0.09	0.0
d (married vs. unknown)	0.12	0.28	0.26	0.21	− 0.02	− 0.02	0.11	0.11	0.24	0.17	− 0.11	− 0.07
FNCLCC grade
I	90.5	87.7	87.1	89.1	85.4	90.0	93.0	93.4	92.9	94.4	94.4	98.2
II	75.6	69.9	65.7	71.8	83.5	94.4	82.8	74.7	69.4	76.0	88.4	100.0
III	53.8	58.5	66.2	68.0	71.5	78.9	61.2	65.8	72.0	72.0	74.1	81.7
Unknown	72.7	73.6	77.4	77.8	79.7	79.1	77.6	78.2	81.7	82.6	85.3	85.6
d (I vs. II)	0.33	0.40	0.50	0.42	0.05	− 0.11	0.24	0.46	0.60	0.49	0.17	− 0.05
d (I vs. III)	0.82	0.65	0.50	0.51	0.35	0.27	0.76	0.67	0.54	0.59	0.56	0.47
d (I vs. Unknown)	0.40	0.32	0.23	0.27	0.14	0.66	0.37	0.37	0.29	0.31	0.25	0.36
Size (cm)
< 5	84.8	80.9	87.0	87.3	75.1	71.8	90.9	86.4	91.7	89.1	75.1	71.8
5–10	75.4	75.9	79.0	82.1	88.1	90.4	80.6	80.8	82.9	85.5	89.5	92.4
10–15	72.5	69.0	75.4	78.3	80.6	80.6	78.6	75.5	80.5	82.9	86.4	87.3
≥ 15	69.0	72.6	75.6	76.6	77.2	76.7	74	77.3	80.5	81.5	83.5	84.6
Unknown	74.1	66.9	67.5	61.0	66.9	57.2	79.5	73.8	74.6	74.1	83.7	74.8
d (< 5 vs. 5–10)	0.21	0.11	0.19	0.13	− 0.33	− 0.45	0.25	0.14	0.23	0.09	− 0.40	− 0.59
d (< 5 vs. 10–15)	0.27	0.26	0.28	0.22	0.14	− 0.21	0.29	0.27	0.29	0.16	− 0.31	− 0.44
d (< 5 vs. ≥ 15)	0.35	0.18	0.27	0.26	0.05	− 0.12	0.40	0.22	0.29	0.20	− 0.23	− 0.37
d (< 5 vs. Unknown)	0.24	0.32	0.46	0.63	0.20	0.89	0.27	0.30	0.44	0.40	− 0.24	− 0.09
Multifocality
No	69.7	70.4	74.7	76.7	79.6	79.1	73.6	74.2	77.8	79.5	87.1	83.1
Yes	84.1	85.6	84.6	82.9	79.6	79.7	97.5	98.4	97.5	95.9	94.7	96.0
d (No vs. Yes)	− 0.32	− 0.34	− 0.24	− 0.15	0	− 0.01	− 0.57	− 0.59	− 0.51	− 0.43	− 0.21	− 0.37
Histology
SFT	86.7	86.7	88.9	88.9	76.2	68.6	86.7	86.7	88.9	88.9	76.2	68.6
MFHC	41.7	56.0	66.7	80.0	64.3	50.0	49.2	62.0	70.6	80	71.4	64.8
MPNST	62.3	63.5	71.4	55.6	66.7	66.7	76.2	76.2	85.7	100.0	100.0	100.0
LMS	70.2	67.4	71.6	73.4	79.6	84.1	75.6	72.6	75.6	75.7	81.6	85.7
DD lipo	63.6	65.8	66.6	66.7	66.5	68.2	68.7	70.7	72.4	72.3	74.2	76.9
WD lipo	90.4	88.0	88.5	86.3	88.2	86.3	95.6	93.8	94.2	91.7	92.4	91.7
Other	67.9	71.3	77.5	81.0	82.2	80.1	72.7	76.1	81.5	86.4	88.9	88.7
d (SFT vs. MFHC)	1.00	0.68	0.53	0.22	0.30	0.45	0.89	0.60	0.47	0.23	0.13	0.11
d (SFT vs. MPNST)	0.54	0.52	0.42	0.81	0.24	0.05	0.25	0.26	0.08	− 0.29	− 0.66	− 0.90
d (SFT vs. LMS)	0.37	0.43	0.41	0.38	− 0.09	− 0.38	0.26	0.34	0.34	0.35	− 0.15	− 0.49
d (SFT vs. DD lipo)	0.51	0.46	0.53	0.54	0.24	0.01	0.43	0.39	0.42	0.44	0.06	− 0.24
d (SFT vs. WD lipo)	− 0.08	− 0.03	0.01	0.06	− 0.30	− 0.43	− 0.21	− 0.17	− 0.14	− 0.07	− 0.45	− 0.66
d (SFT vs. Other)	0.42	0.34	0.27	0.19	− 0.15	− 0.28	0.33	0.26	0.19	0.07	− 0.35	− 0.57
Chemotherapy
No	74.9	75.9	78.8	79.8	81.3	80.2	80.6	81.3	83.8	84.5	86.5	86.7
Yes	53.8	53.9	60.6	63.2	66.2	71.2	56.2	58.0	64.1	68.6	72.2	77.7
d (No vs. Yes)	0.47	0.49	0.43	0.40	0.38	0.22	0.58	0.57	0.51	0.42	0.40	0.26

SFT solitary fibrous tumor, MFHC Malignant fibrous histiocytoma, MPNST malignant peripheral nerve sheath tumor, LMS leiomyosarcoma, DD lipo dedifferentiated liposarcoma, WD lipo well-differentiated liposarcoma, FNCLCC French National Federation of the Centers for the Fight Against Cancer, API Asian/Pacific Islander, COS3 3-year conditional overall survival, CCSS3 3-year conditional cancer-specific survival, y year, d standardized difference

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com